{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:26:02Z","timestamp":1793316362903,"version":"4.5.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Direct"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Orthotopic liver transplantation (OLT) is a potential curative treatment in patients with hepatocellular carcinoma (HCC); however, treatment options for recurrent HCC after OLT are limited. Immune checkpoint inhibitors, such as nivolumab, an inhibitor of programmed cell death protein 1, have been successfully used for metastatic HCC but data on safety of nivolumab following solid organ transplantation are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We report a 53-year-old woman with HCC who was treated with OLT. After 2 years, HCC recurred. Initial treatment with sorafenib was discontinued due to side effects and disease progression. Progressive HCC in the lung and lymph nodes was subsequently treated with nivolumab. One week after the first nivolumab dose, rapid progressive liver dysfunction was noted. Liver biopsy revealed severe cellular graft rejection prompting treatment with intravenous steroids and tacrolimus. Liver function continued to decline, leading to severe coagulopathy. The patient succumbed to intracranial hemorrhage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A systematic PubMed search revealed 29 cases treated with a checkpoint inhibitor following solid organ transplantation. Loss of graft was described in 4 (36%) of 11 cases with OLT and in 7 (54%) of 13 cases after kidney transplantation. However, cases with favorable outcome were also described. Eighteen cases with adverse events were identified upon searching the World Health Organization database VigiBase, including 2 cases with fatal outcome in liver transplant recipients due to graft loss.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Experience with checkpoint inhibitors in solid organ transplant recipients is limited. Published cases so far suggest severe risks for graft loss as high as 36% to 54%.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000000814","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T01:11:33Z","timestamp":1532135493000},"page":"e376","source":"Crossref","is-referenced-by-count":122,"title":["Liver Allograft Failure After Nivolumab Treatment\u2014A Case Report With Systematic Literature Research"],"prefix":"10.1097","volume":"4","author":[{"given":"Dimitri","family":"Gassmann","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Weiler","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim C.","family":"Mertens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e4cilia S.","family":"Reiner","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic and Interventional Radiology, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Vrugt","sequence":"additional","affiliation":[{"name":"Institute of Pathology and Molecular Pathology, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"N\u00e4geli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"M\u00fcllhaupt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Jenni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Misselwitz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,8]]},"reference":[{"key":"bib1-20231002","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.3748\/wjg.v21.i39.11185","article-title":"Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review","volume":"21","year":"2015","journal-title":"World J Gastroenterol"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","year":"1996","journal-title":"N Engl J Med"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"bib4-20231002","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/lt.23911","article-title":"Sorafenib use in the transplant setting","volume":"20","year":"2014","journal-title":"Liver Transpl"},{"key":"bib5-20231002","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bcpt.12365","article-title":"The adverse effects of sorafenib in patients with advanced cancers","volume":"116","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"bib6-20231002","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"Suppl 1","key":"bib7-20231002","first-page":"50","article-title":"Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials","volume":"92","year":"2017","journal-title":"Oncology"},{"key":"bib8-20231002","first-page":"331","article-title":"Excellent response to anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature","volume":"23","year":"2017","journal-title":"Discov Med"},{"key":"bib9-20231002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.21037\/jgo.2017.03.13","article-title":"Locoregional and systemic therapy for hepatocellular carcinoma","volume":"8","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"bib11-20231002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-015-0066-0","article-title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","volume":"3","year":"2015","journal-title":"J Immunother Cancer"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/CJI.0000000000000077","article-title":"Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma","volume":"38","year":"2015","journal-title":"J Immunother"},{"key":"bib13-20231002","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mdx281","article-title":"Acute liver graft rejection after ipilimumab therapy","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib14-20231002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CMR.0000000000000410","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review","volume":"28","year":"2018","journal-title":"Melanoma Res"},{"key":"bib15-20231002","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma","volume":"64","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"bib16-20231002","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/j.gastro.2017.01.063","article-title":"Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient","volume":"152","year":"2017","journal-title":"Gastroenterology"},{"key":"bib17-20231002","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdx548","article-title":"Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"key":"bib18-20231002","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.29575","article-title":"Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet?","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"bib19-20231002","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/L17-0187","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma","volume":"167","year":"2017","journal-title":"Ann Intern Med"},{"key":"bib20-20231002","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib21-20231002","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1016\/j.transproceed.2016.07.019","article-title":"Renal allograft failure after ipilimumab therapy for metastatic melanoma: a case report and review of the literature","volume":"48","year":"2016","journal-title":"Transplant Proc"},{"key":"bib22-20231002","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2016.07.026","article-title":"Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient","volume":"67","year":"2016","journal-title":"Eur J Cancer"},{"key":"bib23-20231002","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jdcr.2017.06.005","article-title":"Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade","volume":"3","year":"2017","journal-title":"JAAD Case Rep"},{"key":"bib24-20231002","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","year":"2016","journal-title":"Ann Oncol"},{"key":"bib25-20231002","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib26-20231002","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.13786","article-title":"Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"bib27-20231002","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CJI.0000000000000180","article-title":"Immune checkpoint inhibitors in organ transplant patients","volume":"40","year":"2017","journal-title":"J Immunother"},{"key":"bib28-20231002","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CJI.0000000000000188","article-title":"Safe administration of an anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature","volume":"40","year":"2017","journal-title":"J Immunother"},{"key":"bib29-20231002","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","article-title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","volume":"4","year":"2016","journal-title":"J Immunother Cancer"},{"key":"bib30-20231002","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib31-20231002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13256-017-1229-z","article-title":"Pembrolizumab formetastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report","volume":"11","year":"2017","journal-title":"J Med Case Reports"},{"key":"bib32-20231002","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/annonc\/mdw293","article-title":"Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient","volume":"27","year":"2016","journal-title":"Ann Oncol"},{"key":"bib33-20231002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-016-1918-2","article-title":"Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report","volume":"66","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"bib34-20231002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2016.10.008","article-title":"Corneal graft rejection in a patient treated with nivolumab for primary lung cancer","volume":"102","year":"2016","journal-title":"Lung Cancer"},{"key":"bib35-20231002","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.510250328","article-title":"Banff schema for grading liver allograft rejection: an international consensus document","volume":"25","year":"1997","journal-title":"Hepatology"},{"key":"bib36-20231002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","year":"2016","journal-title":"Transplantation"},{"key":"bib37-20231002","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/pds.2630010207","article-title":"Causality classification at pharmacovigilance centres in the European Community","volume":"1","year":"1992","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"bib38-20231002","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","year":"2017","journal-title":"Am J Nephrol"},{"key":"bib39-20231002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-6143.2009.02859.x","article-title":"PD-1\/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"bib40-20231002","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"bib41-20231002","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and its ligands are important immune checkpoints in cancer","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib42-20231002","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.4049\/jimmunol.174.11.6648","article-title":"Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo","volume":"174","year":"2005","journal-title":"J Immunol"},{"key":"bib43-20231002","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.4049\/jimmunol.179.8.5204","article-title":"PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection","volume":"179","year":"2007","journal-title":"J Immunol"},{"key":"bib44-20231002","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","year":"2011","journal-title":"Nat Immunol"},{"key":"bib45-20231002","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1600-6143.2005.00823.x","article-title":"CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance","volume":"5","year":"2005","journal-title":"Am J Transplant"},{"key":"bib46-20231002","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.4049\/jimmunol.162.4.1947","article-title":"The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival","volume":"162","year":"1999","journal-title":"J Immunol"},{"key":"bib47-20231002","first-page":"76","article-title":"Managing immune checkpoint-blocking antibody side effects","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"bib48-20231002","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-1007379","article-title":"Treatment of acute rejection","volume":"12","year":"1992","journal-title":"Semin Liver Dis"},{"key":"bib49-20231002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"bib50-20231002","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1007\/s10620-010-1149-x","article-title":"Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation","volume":"55","year":"2010","journal-title":"Dig Dis Sci"},{"key":"bib51-20231002","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.3748\/wjg.15.3426","article-title":"Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation","volume":"15","year":"2009","journal-title":"World J Gastroenterol"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01845228-201808000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:11:10Z","timestamp":1696230670000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01845228-201808000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000000814","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}